Medical News Podcast

Drs. Gina Woods and Susan V. Bukata review surgical care, including joint replacement and spine surgery, in patients with osteoporosis. They discuss the planning and operative techniques that help improve outcomes in these patients.

Drs. Susan V. Bukata and Gina Woods discuss the perioperative care of patients with osteoporotic fractures and those with osteoporosis undergoing elective surgery.

Learn about OXO-001, a non-hormonal drug that increases pregnancy rates in women undergoing IVF or ICSI by enhancing embryo implantation. Also in this episode: patients with type 2 diabetes taking GLP-1 receptor agonists have a lower risk of certain obesity-associated cancers compared to those on insulin, though no significant reduction compared to metformin. Finally, the third story highlights re...

Dr. Susan V. Bukata and Freda B. Hannafon, NP‑C, discuss the role of nurse practitioners and physician assistants in the care of patients with postmenopausal osteoporosis, including diagnosis, management, and collaboration with endocrinologists and orthopedic surgeons.

Drs. Mattingly and McIntyre continue their discussion about their insights into the role of emerging and novel mechanisms of action for potential treatments of schizophrenia, particularly those addressing the negative and cognitive symptoms.

Drs. Roger McIntyre and Greg Mattingly share their insights into the role of emerging and novel mechanisms of action for potential treatments of schizophrenia, particularly those addressing the negative and cognitive symptoms.

In the second part of this series, Drs. Henry A. Nasrallah and Dawn Velligan continue sharing their insights into the importance of assessing and screening for cognitive impairment in patients with schizophrenia. They discuss why testing for cognitive impairment in standard clinical practice isn’t more widespread, the barriers clinicians face in testing, and the misconception that testing for cogn...

Drs. Dawn Velligan and Henry A. Nasrallah share their insights into the importance of assessing and screening for cognitive impairment in patients with schizophrenia. They discuss why testing for cognitive impairment in standard clinical practice isn’t more widespread, the barriers clinicians face in testing, and the misconception that testing for cognitive impairment is prohibitive due to the res...

Dr. Gus Alva and Ms. Sheena Patel, PA-C, continue their conversation, sharing insights into the three symptom domains of schizophrenia: positive, negative, and cognitive impairment. They discuss how each of these symptom domains could present in the outpatient clinical practice, with particular focus on negative symptoms and cognitive impairment.

Can a new drug slow the progression of Alzheimer's disease? Find out about this and more in today's PeerDirect Medical News Podcast.

Ms. Sheena Patel, PA-C, and Dr. Gus Alva share their insights into the three symptom domains of schizophrenia: positive, negative, and cognitive impairment, and how each of these symptom domains could present in the outpatient clinical practice. In particular, they discuss the less obvious domains: negative symptoms and cognitive impairment.

Can islet cell transplant eliminate the need for insulin in patients with type 1 diabetes? Find out about this and more in today's PeerDirect Medical News Podcast.

Can the use of hearing aids slow down cognitive decline? Find out about this and more in today's PeerDirect Medical News Podcast.

Drs. Claudine Isaacs and Filipa Lynce conclude their discussion on the highlights of ASCO 2024 Annual Meeting, with a focus on HER2+ breast cancer. They discussed results from the Destiny Breast 07 trial, highlighting the efficacy of TDXD alone and in combination with pertuzumab in first-line treatment of HER2-positive breast cancer. The study showed high overall response rates and promising progr...

Drs. Claudine Isaacs and Filipa Lynce continue their discussion on the highlights of ASCO 2024 Annual Meeting, with a focus on HER2+ breast cancer. In part two of the discussion, the focus is on two studies pertaining to HER2-positive breast cancer. The first study, the GBCRG-M06 Emerald Study compared the effectiveness and toxicity of eribulin mesylate versus a taxane (with trastuzumab and pertuz...

Drs. Claudine Isaacs and Filipa Lynce discuss highlights of the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, with a focus on HER2+ breast cancer, including late-breaking abstracts such as DESTINY‑Breast06 and others.

How many patients maintain weight loss 1 year after discontinuing semaglutide or liraglutide? Find out about this and more in today's PeerDirect Medical News Podcast.

Which drug keeps lung cancer from progressing for over 5 years? Find out about this and more in today's PeerDirect Medical News Podcast.

Could tattoos be a risk factor for malignant lymphoma? Find out about this and more in today's PeerDirect Medical News Podcast.

This week's stories include an endoscopic ablation technique targeting ghrelin production showing results for significant weight loss, research that prior immunity to SARS-CoV-2 does not inhibit response to updated COVID-19 vaccines, and a study from the 2024 Heart Rhythm Society Meeting suggesting oral anticoagulant discontinuation after atrial fibrillation catheter ablation may be feasible and s...

Drs. David Eichenbaum and Priya Vakharia share their insights on biosimilars in the treatment of retinal disease in the United States.

Is there potential for recovery in patients who are withdrawn from life support? Find out about this and more in today's PeerDirect Medical News Podcast.

Drs. David Eichenbaum and Priya Vakharia share their insights on biosimilars in the treatment of retinal disease in the United States.

Drs. Alicia Morgans and Jonathan Rosenberg share their insights into some interesting abstracts from the 2024 ASCO GU symposium: one covering a model to help predict response to neoadjuvant chemotherapy in patients with muscle invasive UC, and another regarding results from the PemCab study of pembrolizumab and cabozantinib in first‑line advanced UC.

Drs. Jonathan Rosenberg and Alicia Morgans share their insights into some late-breaker abstracts presented at the 2024 ASCO GU symposium in San Francisco. The first is a subgroup analysis from EV‑302 with enfortumab vedotin and pembrolizumab, and the other is AMBASSADOR, which looks at adjuvant pembrolizumab in locally advanced and muscle invasive urothelial cancer.